Login to Your Account



NeuroNova Going to Newron via $19M Stock-based Deal

By Cormac Sheridan
Staff Writer

Thursday, June 14, 2012
Newron Pharmaceuticals SpA is taking over NeuroNova AB in a stock-based deal valued at €15.4 million (US$19.4 million), which will add two clinical-stage programs to its pipeline of drugs for neurodegenerative disease and €16 million in fresh funding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription